



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

**OV809b** : Ovary cancer with ovary tissue array, including pathology grade, TNM and clinical stage, 80 cases/80 cores, replacing OV809a

|                    |  |  |
|--------------------|--|--|
| Microarray Panel   | Ovarian carcinoma with ovary tissue microarray, containing 54 cases of serous carcinoma, 3 each of clear cell carcinoma and endometrioid carcinoma, 8 mucinous adenocarcinoma, 2 malignant Brenner tumor, 8 adjacent normal ovary tissue, 2 ovary tissue, single core per case   |  |
| Cores              | 80   |  |
| Cases              | 80   |  |
| Row number         | 8  |  |
| Column number      | 10   |  |
| Core Diameter (mm) | 1.5  |  |
| Thickness (µm)     | 5  |  |
| Tissue Array Type  | FFPE   |  |
| Species            | Human  |  |
| Applications       | Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.   |  |
| Notes              | <p>1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). <b>To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C.</b> before putting into xylene for deparaffinization. Baked slides were sent out baked for 2 hours.</p> <p>In the following specsheet, “*” means invalid core; “-” means no applicable or negative in IHC markers.</p> |  |



Legend: Ova - Ovary

- - Malignant tumor, ○ - Malignant tumor (stage I), ○ - Malignant tumor (stage IA), ○ - Malignant tumor (stage IB), ● - Malignant tumor (stage II), ● - Malignant tumor (stage IIA), ● - Malignant tumor (stage IIB), ● - Malignant tumor (stage IIC), ● - Malignant tumor (stage III), ● - Malignant tumor (stage IIIA), ● - Malignant tumor (stage IIIB), ● - Malignant tumor (stage IIIC), ● - Malignant tumor (stage IV), ● - NAT, ● - Normal tissue

| Pos. | No. | Age | Sex | Organ/Anatomic Site | Pathology diagnosis               | TNM     | Grade | Stage | Type      |
|------|-----|-----|-----|---------------------|-----------------------------------|---------|-------|-------|-----------|
| A1   | 1   | 42  | F   | Ovary               | Mucinous adenocarcinoma           | T1bN0M0 | 2     | IB    | Malignant |
| A2   | 2   | 35  | F   | Ovary               | High grade serous carcinoma       | T1aN0M0 | -     | IA    | Malignant |
| A3   | 3   | 41  | F   | Ovary               | High grade serous carcinoma       | T1aN0M0 | -     | IA    | Malignant |
| A4   | 4   | 60  | F   | Ovary               | High grade serous carcinoma       | T1aN0M0 | -     | IA    | Malignant |
| A5   | 5   | 57  | F   | Ovary               | High grade serous carcinoma       | T1aN0M0 | -     | IA    | Malignant |
| A6   | 6   | 60  | F   | Ovary               | High grade serous carcinoma       | T1aN0M0 | -     | IA    | Malignant |
| A7   | 7   | 39  | F   | Ovary               | High grade serous carcinoma       | T1aN0M0 | -     | IA    | Malignant |
| A8   | 8   | 53  | F   | Ovary               | High grade serous carcinoma       | T1aN0M0 | -     | IA    | Malignant |
| A9   | 9   | 39  | F   | Ovary               | High grade serous carcinoma       | T1aN0M0 | -     | IA    | Malignant |
| A10  | 10  | 52  | F   | Ovary               | Endometrioid carcinoma            | T1aN0M0 | 1     | IA    | Malignant |
| B1   | 11  | 49  | F   | Ovary               | Endometrioid carcinoma            | T1aN0M0 | *     | IA    | Malignant |
| B2   | 12  | 70  | F   | Ovary               | Malignant Brenner tumor           | T1N0M0  | -     | I     | Malignant |
| B3   | 13  | 61  | F   | Ovary               | Clear cell carcinoma              | T1aN0M0 | -     | IA    | Malignant |
| B4   | 14  | 39  | F   | Ovary               | Clear cell carcinoma              | T1N0M0  | -     | I     | Malignant |
| B5   | 15  | 42  | F   | Ovary               | Clear cell carcinoma              | T1aN0M0 | -     | IA    | Malignant |
| B6   | 16  | 19  | F   | Ovary               | Mucinous adenocarcinoma           | T2aN0M0 | 1-2   | IIA   | Malignant |
| B7   | 17  | 38  | F   | Ovary               | Mucinous papillary adenocarcinoma | T2bNxM0 | 1     | IIB   | Malignant |
| B8   | 18  | 44  | F   | Ovary               | Mucinous papillary adenocarcinoma | T3cN0M0 | 1     | IIIC  | Malignant |

|     |    |    |   |               |  |         |     |      |           |
|-----|----|----|---|---------------|--|---------|-----|------|-----------|
| B9  | 19 | 35 | F | Ovary         | Mucinous papillary adenocarcinoma              | T3aN1M0 | 1   | IIIC | Malignant |
| B10 | 20 | 48 | F | Ovary         | Mucinous adenocarcinoma                        | T3cN0M0 | 2–3 | IIIC | Malignant |
| C1  | 21 | 50 | F | Ovary         | Mucinous adenocarcinoma                        | T3cN1M0 | 3   | IIIC | Malignant |
| C2  | 22 | 48 | F | Ovary         | Mucinous adenocarcinoma                        | T3aN1M1 | 2   | IV   | Malignant |
| C3  | 23 | 49 | F | Ovary         | High grade serous carcinoma                    | T2N0M0  | -   | II   | Malignant |
| C4  | 24 | 52 | F | Ovary         | High grade serous carcinoma                    | T2N0M0  | -   | II   | Malignant |
| C5  | 25 | 42 | F | Ovary         | High grade serous carcinoma                    | T2N0M0  | -   | II   | Malignant |
| C6  | 26 | 53 | F | Ovary         | High grade serous carcinoma (sparse)           | T2aN0M0 | -   | IIA  | Malignant |
| C7  | 27 | 38 | F | Ovary         | High grade serous papillary carcinoma          | T2bN0M0 | -   | IIB  | Malignant |
| C8  | 28 | 48 | F | Ovary         | High grade serous carcinoma                    | T2bN0M0 | -   | IIB  | Malignant |
| C9  | 29 | 22 | F | Ovary         | High grade serous carcinoma                    | T2bN0M0 | -   | IIB  | Malignant |
| C10 | 30 | 42 | F | Ovary         | High grade serous carcinoma                    | T2bN0M0 | -   | IIB  | Malignant |
| D1  | 31 | 66 | F | Ovary         | High grade serous carcinoma                    | T2bN0M0 | -   | IIB  | Malignant |
| D2  | 32 | 60 | F | Ovary         | High grade serous carcinoma                    | T2bN0M0 | -   | IIB  | Malignant |
| D3  | 33 | 76 | F | Ovary         | High grade serous papillary carcinoma          | T2cN0M0 | -   | IIC  | Malignant |
| D4  | 34 | 49 | F | Ovary         | High grade serous carcinoma                    | T2cN0M0 | -   | IIC  | Malignant |
| D5  | 35 | 53 | F | Ovary         | High grade serous carcinoma                    | T3N0M0  | -   | III  | Malignant |
| D6  | 36 | 59 | F | Ovary         | High grade serous papillary carcinoma          | T3aN0M0 | -   | IIIA | Malignant |
| D7  | 37 | 52 | F | Ovary         | High grade serous carcinoma (sparse)           | T3aN0M0 | -   | IIIA | Malignant |
| D8  | 38 | 48 | F | Ovary         | High grade serous carcinoma                    | T3aN0M0 | -   | IIIA | Malignant |
| D9  | 39 | 50 | F | Ovary         | High grade serous papillary carcinoma          | T3aN0M0 | -   | IIIA | Malignant |
| D10 | 40 | 47 | F | Ovary         | High grade serous carcinoma                    | T3bN0M0 | -   | IIIB | Malignant |
| E1  | 41 | 53 | F | Ovary         | High-grade serous papillary cystadenocarcinoma | T3bN0M0 | -   | IIIB | Malignant |
| E2  | 42 | 54 | F | Ovary         | High grade serous carcinoma                    | T3cN0M0 | -   | IIIC | Malignant |
| E3  | 43 | 41 | F | Ovary         | High grade serous carcinoma                    | T3cN0M0 | -   | IIIC | Malignant |
| E4  | 44 | 39 | F | Ovary         | High grade serous carcinoma                    | T3cN0M0 | -   | IIIC | Malignant |
| E5  | 45 | 53 | F | Ovary         | High grade serous carcinoma                    | T3N1M0  | -   | IIIC | Malignant |
| E6  | 46 | 47 | F | Ovary         | High grade serous papillary carcinoma          | T3bN1M0 | -   | IIIC | Malignant |
| E7  | 47 | 43 | F | Ovary         | High grade serous papillary carcinoma          | T3N1M0  | -   | IIIC | Malignant |
| E8  | 48 | 42 | F | Ovary         | High grade serous carcinoma                    | T3cN1M0 | -   | IIIC | Malignant |
| E9  | 49 | 43 | F | Ovary         | High grade serous papillary carcinoma          | T3cN0M0 | -   | IIIC | Malignant |
| E10 | 50 | 48 | F | Ovary         | Low grade serous papillary carcinoma           | T2N1M0  | -   | IIIC | Malignant |
| F1  | 51 | 54 | F | Ovary         | High grade serous papillary carcinoma          | T3N1M0  | -   | IIIC | Malignant |
| F2  | 52 | 63 | F | Ovary         | High grade serous carcinoma                    | T2N1M0  | -   | IIIC | Malignant |
| F3  | 53 | 63 | F | Ovary         | High grade serous papillary carcinoma          | T3cN1M0 | -   | IIIC | Malignant |
| F4  | 54 | 49 | F | Ovary         | High grade serous papillary carcinoma          | T3aN1M0 | -   | IIIC | Malignant |
| F5  | 55 | 49 | F | Ovary         | High grade serous papillary carcinoma          | T3bN1M0 | -   | IIIC | Malignant |
| F6  | 56 | 49 | F | Ovary         | High grade serous carcinoma                    | T3cN1M0 | -   | IIIC | Malignant |
| F7  | 57 | 64 | F | Ovary         | High grade serous carcinoma                    | T3cN1M0 | -   | IIIC | Malignant |
| F8  | 58 | 37 | F | Ovary         | High grade serous papillary carcinoma          | T3cN0M0 | -   | IIIC | Malignant |
| F9  | 59 | 40 | F | Ovary         | High grade serous carcinoma                    | T2N1M0  | -   | IIIC | Malignant |
| F10 | 60 | 46 | F | Ovary         | High grade serous carcinoma                    | T2N1M0  | -   | IIIC | Malignant |
| G1  | 61 | 54 | F | Ovary         | High grade serous papillary carcinoma          | T3cN1M0 | -   | IIIC | Malignant |
| G2  | 62 | 51 | F | Ovary         | High grade serous papillary carcinoma          | T3cN1M0 | -   | IIIC | Malignant |
| G3  | 63 | 43 | F | Ovary         | High grade serous carcinoma                    | T3cN1M0 | -   | IIIC | Malignant |
| G4  | 64 | 59 | F | Ovary         | High grade serous papillary carcinoma          | T3N1M1  | -   | IV   | Malignant |
| G5  | 65 | 64 | F | Ovary         | High grade serous carcinoma                    | T3cN1M1 | -   | IV   | Malignant |
| G6  | 66 | 47 | F | Ovary         | High grade serous papillary carcinoma          | T3cN1M1 | -   | IV   | Malignant |
| G7  | 67 | 63 | F | Ovary         | High grade serous carcinoma                    | T2N1M1  | -   | IV   | Malignant |
| G8  | 68 | 54 | F | Ovary         | High grade serous carcinoma                    | T3N1M1  | -   | IV   | Malignant |
| G9  | 69 | 47 | F | Ovary         | Endometrioid carcinoma (sparse)                | T2aN0M0 | 1   | IIA  | Malignant |
| G10 | 70 | 55 | F | Ovary         | Malignant Brenner tumor                        | T3cN0M0 | -   | IIIC | Malignant |
| H1  | 71 | 42 | F | Ovary         | Adjacent normal ovary tissue                   | -       | -   | -    | NAT       |
| H2  | 72 | 42 | F | Ovary         | Adjacent normal ovary tissue                   | -       | -   | -    | NAT       |
| H3  | 73 | 48 | F | Ovary         | Adjacent normal ovary tissue                   | -       | -   | -    | NAT       |
| H4  | 74 | 51 | F | Ovary         | Adjacent normal ovary tissue                   | -       | -   | -    | NAT       |
| H5  | 75 | 42 | F | Ovary         | Adjacent normal ovary tissue                   | -       | -   | -    | NAT       |
| H6  | 76 | 41 | F | Ovary         | Adjacent normal ovary tissue                   | -       | -   | -    | NAT       |
| H7  | 77 | 38 | F | Ovary         | Adjacent normal ovary tissue                   | -       | -   | -    | NAT       |
| H8  | 78 | 51 | F | Ovary         | Adjacent normal ovary tissue                   | -       | -   | -    | NAT       |
| H9  | 79 | 20 | F | Ovary         | Ovary tissue                                   | -       | -   | -    | Normal    |
| H10 | 80 | 54 | F | Ovary         | Ovary tissue                                   | -       | -   | -    | Normal    |
| -   | 0  | 42 | M | Adrenal gland | Pheochromocytoma (tissue marker)               | -       | -   | -    | Malignant |

**TNM and FIGO classification, staging of tumors of the ovary, fallopian tube and primary peritoneal carcinoma:**

**TNM Primary tumor (T) and FIGO stages in ( )**

- TX: Primary tumor cannot be assessed
- T0: No evidence of primary tumor
- T1(I): Tumor limited to the ovaries
- T1a(IA): Tumor limited to one ovary (capsule intact) or fallopian tube surface; no malignant cells in ascites or peritoneal washings
- T1b(IB): Tumor limited to one or both ovaries (capsules intact) or fallopian tubes; no tumor on ovarian or fallopian tube surface, no malignant cells in ascites or peritoneal washings
- T1c(IC): Tumor limited to one or both ovaries or fallopian tubes with any of following:
- T2a(IIA): Extension and/or implants on uterus and/or fallopian tubes and/or ovaries; no malignant cells in ascites or peritoneal washings
- T2b(IIB): Extension to other pelvic intraperitoneal tissues
- T3(III): Tumor involves one or both ovaries or fallopian tubes, or primary and/or peritoneal cancer, with cytologically or histologically confirmed
- T3a(IIIA): Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes
- T3b(IIIB): Macroscopic peritoneal metastasis beyond pelvis up to 2 cm in greatest dimension or less in greatest dimension with or without retroperitoneal lymph node metastasis
- T3c(IIIC): Macroscopic peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension with or without retroperitoneal lymph node metastasis (excludes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ)

**TRegional lymph nodes (N) and FIGO stages in ( )**

- NX: Regional lymph nodes cannot be assessed
- N0: No regional lymph node metastasis
- N1 (IIIC): Regional lymph node metastasis

**TDistant metastasis (M) and FIGO stages in ( )**

- M0: No distant metastasis
- M1 (IV): Distant metastasis

**AMSBIO | [www.amsbio.com](http://www.amsbio.com) | [info@amsbio.com](mailto:info@amsbio.com)**

 **UK & Rest of the World**  
184 Park Drive, Milton Park  
Abingdon OX14 4SE, UK  
T: +44 (0)1235 828 200  
F: +44 (0) 1235 820 482

 **North America**  
1035 Cambridge Street,  
Cambridge, MA 02141  
T: +1 (617) 945-5033 or  
T: +1 (800) 987-0985  
F: +1 (617) 945-8218

 **Germany**  
Bockenheimer Landstr. 17/19  
60325 Frankfurt/Main  
T: +49 (0) 69 779099  
F: +49 (0) 69 13376880

 **Switzerland**  
Centro Nord-Sud 2E  
CH-6934 Bioggio-Lugano  
T: +41(0) 91 604 55 22  
F: +41(0) 91 605 17 85